Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with tacrolimus reduction or elimination versus tacrolimus after de novo liver transplantation
2007-001821-85Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, tacrolimus and mycophenolate mofetil in liver transplant (3 arms), sponsored by Novartis. Primary endpoint: Renal function at 12 months. Started Nov 2007; status: completed.
02
Drugs
everolimustacrolimusmycophenolate mofetil
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2007-001821-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001821-85.